1. Home
  2. NVCR vs TFIN Comparison

NVCR vs TFIN Comparison

Compare NVCR & TFIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVCR
  • TFIN
  • Stock Information
  • Founded
  • NVCR 2000
  • TFIN 1981
  • Country
  • NVCR Jersey
  • TFIN United States
  • Employees
  • NVCR N/A
  • TFIN N/A
  • Industry
  • NVCR Medical/Dental Instruments
  • TFIN Major Banks
  • Sector
  • NVCR Health Care
  • TFIN Finance
  • Exchange
  • NVCR Nasdaq
  • TFIN Nasdaq
  • Market Cap
  • NVCR 1.8B
  • TFIN 2.0B
  • IPO Year
  • NVCR 2015
  • TFIN N/A
  • Fundamental
  • Price
  • NVCR $17.09
  • TFIN $102.19
  • Analyst Decision
  • NVCR Buy
  • TFIN Hold
  • Analyst Count
  • NVCR 5
  • TFIN 5
  • Target Price
  • NVCR $26.60
  • TFIN $71.80
  • AVG Volume (30 Days)
  • NVCR 885.3K
  • TFIN 136.1K
  • Earning Date
  • NVCR 10-30-2024
  • TFIN 10-16-2024
  • Dividend Yield
  • NVCR N/A
  • TFIN N/A
  • EPS Growth
  • NVCR N/A
  • TFIN N/A
  • EPS
  • NVCR N/A
  • TFIN 0.80
  • Revenue
  • NVCR $577,738,000.00
  • TFIN $398,012,000.00
  • Revenue This Year
  • NVCR $19.13
  • TFIN N/A
  • Revenue Next Year
  • NVCR $5.33
  • TFIN $10.19
  • P/E Ratio
  • NVCR N/A
  • TFIN $123.77
  • Revenue Growth
  • NVCR 14.63
  • TFIN N/A
  • 52 Week Low
  • NVCR $11.29
  • TFIN $66.61
  • 52 Week High
  • NVCR $24.74
  • TFIN $105.05
  • Technical
  • Relative Strength Index (RSI)
  • NVCR 52.30
  • TFIN 66.10
  • Support Level
  • NVCR $15.35
  • TFIN $96.31
  • Resistance Level
  • NVCR $17.35
  • TFIN $105.05
  • Average True Range (ATR)
  • NVCR 0.98
  • TFIN 3.51
  • MACD
  • NVCR -0.06
  • TFIN 0.04
  • Stochastic Oscillator
  • NVCR 52.41
  • TFIN 85.10

About NVCR NovoCure Limited

NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

About TFIN Triumph Financial Inc.

Triumph Financial Inc is a is a financial holding company. The company has four reportable segments namely Banking, Factoring, Payments, and Corporate. The Banking segment includes the operations of TBK Bank. The Factoring segment includes the operations of Triumph Financial Services with revenue derived from factoring services, The Payments segment includes the operations of TBK Bank's TriumphPay division which provides a presentment, audit and payment solution to Shipper, Broker, and Factor clients in the trucking industry and The corporate segment includes holding company financing and investment activities and management and administrative expenses to support the overall operations of the Company.

Share on Social Networks: